Key clinical point: The ongoing Beat AML Master Trial demonstrates the feasibility of delivering rapid genomic results for personalized treatment in newly diagnosed acute myeloid leukemia.
Major finding: More than 95% of patients in the trial were assigned to treatment within 7 days based on results of their genomic screening.
Study details: An umbrella study of 285 patients aged 60 years and older with newly diagnosed acute myeloid leukemia.
Disclosures: The study is sponsored by the Leukemia & Lymphoma Society. Dr. Burd is an employee of the Society and other investigators reported funding from multiple pharmaceutical companies.
Burd A et al. ASH 2018, Abstract 559.